RecruitingNCT07136623

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

Deep Learning for Algorithmic Detection of Pulmonary Hypertension Using a Combined Digital Stethoscope and Three-lead Electrocardiogram


Sponsor

Eko Devices, Inc.

Enrollment

1,513 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective, observational study will evaluate whether synchronized heart sound (phonocardiogram, PCG) and three-lead electrocardiogram (ECG) recordings (entered as separate interventions in PRS, though collected together in practice) collected with the Eko CORE 500 can help screen for pulmonary hypertension (PH). Adults (≥18 years) undergoing clinically indicated transthoracic echocardiography (TTE) and/or right heart catheterization (RHC) will complete one study visit (\~20 minutes). During the visit, study staff will obtain at least four 15-second CORE 500 recordings (aortic, pulmonic, tricuspid, and mitral areas). The clinical echocardiogram (and RHC, if performed) within ±7 days of the recordings will provide reference labels for the presence and severity of PH; de-identified demographic and clinical data may also be abstracted from the medical record. The primary objective is to develop and validate a software algorithm to detect PH and, where possible, stratify severity using noninvasive PCG+ECG signals. These recordings are investigational data acquisitions for algorithm development only; they are not diagnostic procedures and will not be used for clinical decision-making. Primary performance measures are sensitivity and specificity versus echocardiogram and RHC references. No clinical decisions will be based on the investigational algorithm, and no changes to standard care are required. The study plans to enroll up to \~1,513 participants to obtain approximately 1,375 evaluable datasets across multiple outpatient sites.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a digital stethoscope — the Eko CORE 500 — combined with AI analysis can detect pulmonary hypertension (high blood pressure in the arteries supplying the lungs), which is currently difficult to diagnose without invasive or expensive tests. Participants are people already scheduled for an echocardiogram or right heart catheterization. **You may be eligible if...** - You are 18 or older - You are already scheduled for a standard echocardiogram (heart ultrasound) or right heart catheterization within 7 days of the study recording - You are willing and able to give informed consent **You may NOT be eligible if...** - You are unwilling or unable to give consent - You are currently hospitalized at the time of the study procedures - Your scheduled echocardiogram is expected to produce poor-quality or uninterpretable images Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEko CORE 500 phonocardiogram (PCG) recording

Noninvasive acquisition of heart sound (phonocardiogram, PCG) recordings using the FDA (U.S. Food and Drug Administration)-cleared Eko CORE 500 digital stethoscope. At least four 15-second recordings are collected at standard auscultation sites (aortic, pulmonic, tricuspid, mitral). Recordings are used solely for investigational algorithm development and are not used for diagnostic or clinical decision-making.

DIAGNOSTIC_TESTEko CORE 500 three-lead electrocardiogram (ECG) recording

Noninvasive acquisition of three-lead electrocardiogram (ECG) signals using the FDA-cleared Eko CORE 500 digital stethoscope. Recordings are obtained simultaneously with PCG at auscultation sites. Data are used solely for investigational algorithm development and are not intended for diagnostic use.


Locations(2)

University of California Los Angeles

Los Angeles, California, United States

Duke University

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07136623